MX2021015675A - Compuestos de bencil-triazol sustituidos para la inhibicion de cbl-b y otros usos de los mismos. - Google Patents
Compuestos de bencil-triazol sustituidos para la inhibicion de cbl-b y otros usos de los mismos.Info
- Publication number
- MX2021015675A MX2021015675A MX2021015675A MX2021015675A MX2021015675A MX 2021015675 A MX2021015675 A MX 2021015675A MX 2021015675 A MX2021015675 A MX 2021015675A MX 2021015675 A MX2021015675 A MX 2021015675A MX 2021015675 A MX2021015675 A MX 2021015675A
- Authority
- MX
- Mexico
- Prior art keywords
- cbl
- inhibitor
- methods
- bencyl
- inhibition
- Prior art date
Links
- 230000005764 inhibitory process Effects 0.000 title 1
- 229940122650 Cbl-b inhibitor Drugs 0.000 abstract 4
- 238000000034 method Methods 0.000 abstract 4
- 206010028980 Neoplasm Diseases 0.000 abstract 2
- 201000011510 cancer Diseases 0.000 abstract 2
- 229940022399 cancer vaccine Drugs 0.000 abstract 2
- 238000009566 cancer vaccine Methods 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 210000000987 immune system Anatomy 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- 244000309459 oncolytic virus Species 0.000 abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract 2
- 101000737265 Homo sapiens E3 ubiquitin-protein ligase CBL-B Proteins 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 238000000338 in vitro Methods 0.000 abstract 1
- 238000001727 in vivo Methods 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 230000006663 ubiquitin-proteasome pathway Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/50—Cell markers; Cell surface determinants
- C12N2501/515—CD3, T-cell receptor complex
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/50—Cell markers; Cell surface determinants
- C12N2501/599—Cell markers; Cell surface determinants with CD designations not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/999—Small molecules not provided for elsewhere
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Cell Biology (AREA)
- Mycology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962866914P | 2019-06-26 | 2019-06-26 | |
| US201962880285P | 2019-07-30 | 2019-07-30 | |
| US201962888870P | 2019-08-19 | 2019-08-19 | |
| US201962888845P | 2019-08-19 | 2019-08-19 | |
| PCT/US2020/039957 WO2020264398A1 (en) | 2019-06-26 | 2020-06-26 | Substituted benzyl-triazole compounds for cbl-b inhibition, and further uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2021015675A true MX2021015675A (es) | 2022-02-03 |
Family
ID=71662363
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2021015675A MX2021015675A (es) | 2019-06-26 | 2020-06-26 | Compuestos de bencil-triazol sustituidos para la inhibicion de cbl-b y otros usos de los mismos. |
| MX2025000627A MX2025000627A (es) | 2019-06-26 | 2021-12-15 | Compuestos de bencil-triazol sustituidos para la inhibicion de cbl-b y otros usos de los mismos |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2025000627A MX2025000627A (es) | 2019-06-26 | 2021-12-15 | Compuestos de bencil-triazol sustituidos para la inhibicion de cbl-b y otros usos de los mismos |
Country Status (11)
| Country | Link |
|---|---|
| US (3) | US11401267B2 (https=) |
| EP (1) | EP3990117A1 (https=) |
| JP (1) | JP7831995B2 (https=) |
| KR (1) | KR20220026581A (https=) |
| CN (1) | CN114364670B (https=) |
| AU (2) | AU2020303696B2 (https=) |
| BR (1) | BR112021026241A2 (https=) |
| CA (2) | CA3294689A1 (https=) |
| IL (1) | IL289290B1 (https=) |
| MX (2) | MX2021015675A (https=) |
| WO (1) | WO2020264398A1 (https=) |
Families Citing this family (53)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7600123B2 (ja) | 2018-10-15 | 2024-12-16 | ニューリックス セラピューティクス，インコーポレイテッド | ユビキチンプロテオソーム経路を介してｂｔｋを分解するための二官能性化合物 |
| EP3906026A4 (en) | 2018-12-31 | 2022-10-19 | Biomea Fusion, LLC | IRREVERSIBLE INHIBITORS OF MENIN-MLL INTERACTION |
| TW202043205A (zh) | 2018-12-31 | 2020-12-01 | 美商拜歐米富士恩有限公司 | Menin-mll相互作用之抑制劑 |
| WO2020167518A1 (en) | 2019-02-13 | 2020-08-20 | Nurix Therapeutics, Inc. | Bifunctional compounds for degrading btk via ubiquitin proteosome pathway |
| EP3953346A1 (en) * | 2019-04-09 | 2022-02-16 | Nurix Therapeutics, Inc. | 3-substituted piperidine compounds for cbl-b inhibition, and use of a cbl-b inhibitor in combination with a cancer vaccine and/or oncolytic virus |
| EP3969447A1 (en) | 2019-05-17 | 2022-03-23 | Nurix Therapeutics, Inc. | Cyano cyclobutyl compounds for cbl-b inhibition and uses thereof |
| MX2021015675A (es) * | 2019-06-26 | 2022-02-03 | Nurix Therapeutics Inc | Compuestos de bencil-triazol sustituidos para la inhibicion de cbl-b y otros usos de los mismos. |
| EP4034141A1 (en) | 2019-09-24 | 2022-08-03 | Nurix Therapeutics, Inc. | Cbl inhibitors and compositions for expansion of immune cells |
| US11820781B2 (en) | 2019-12-04 | 2023-11-21 | Nurix Therapeutics, Inc. | Bifunctional compounds for degrading BTK via ubiquitin proteosome pathway |
| AR124800A1 (es) * | 2021-02-03 | 2023-05-03 | Genentech Inc | Lactamas como inhibidores cbl-b |
| US12016860B2 (en) | 2021-04-08 | 2024-06-25 | Nurix Therapeutics, Inc. | Combination therapies with Cbl-b inhibitor compounds |
| AU2022256074A1 (en) * | 2021-04-09 | 2023-11-02 | Nimbus Clio, Inc. | Cbl-b modulators and uses thereof |
| BR112023021068A2 (pt) * | 2021-04-16 | 2024-01-23 | Hotspot Therapeutics Inc | Compostos, composições e métodos para tratar câncer |
| WO2022272248A1 (en) * | 2021-06-21 | 2022-12-29 | Nimbus Clio, Inc. | Cbl-b modulators and uses thereof |
| AU2022325861A1 (en) | 2021-08-11 | 2024-02-29 | Biomea Fusion, Inc. | Covalent inhibitors of menin-mll interaction for diabetes mellitus |
| IL310717A (en) | 2021-08-20 | 2024-04-01 | Biomea Fusion Inc | Crystalline form of N-[4-[4-(4-morpholinyl)-7H-PYRROLO[2,3-D]PYRIMIDIN-6-YL]PHENYL]-4-[[3(R)-[(1-OXO ] -2-PROPEN-1-YL)AMINO]-1-PIPERIDINYL]METHYL]-2-PYRIDINECARBOXAMIDE, IRREVERSIBLE MENIN-MLL INHIBITOR FOR CANCER TREATMENT |
| AU2022379494A1 (en) | 2021-10-26 | 2024-05-30 | Nurix Therapeutics, Inc. | Piperidinylpyrazine-carboxamide compounds for treating and preventing cancer and for degrading btk |
| WO2023072273A1 (zh) * | 2021-10-29 | 2023-05-04 | 先声再明医药有限公司 | 作为cbl-b抑制剂的并环化合物 |
| JP2024542117A (ja) * | 2021-11-05 | 2024-11-13 | ジェネンテック， インコーポレイテッド | Ｃ－ｃｂｌに対して選択的なｃｂｌ－ｂ阻害剤としてのラクタム |
| WO2023081486A1 (en) * | 2021-11-08 | 2023-05-11 | Nurix Therapeutics, Inc. | Toll-like receptor therapy combinations with cbl-b inhibitor compounds |
| TW202342013A (zh) * | 2022-02-10 | 2023-11-01 | 英屬開曼群島商百濟神州有限公司 | 雜環化合物、其組成物及用其進行治療之方法 |
| CN116715632B (zh) * | 2022-03-07 | 2025-09-30 | 苏州恩华生物医药科技有限公司 | 螺[环丁烷1,4′-异喹啉]酮类衍生物顺反异构体的制备方法 |
| WO2023170608A1 (en) * | 2022-03-09 | 2023-09-14 | Orum Therapeutics, Inc. | Activators of effector t cells |
| WO2023205180A1 (en) * | 2022-04-19 | 2023-10-26 | Nurix Therapeutics, Inc. | Biomarkers for cbl, and compositions and methods for their use |
| CN119212724A (zh) * | 2022-05-09 | 2024-12-27 | 上海先博生物科技有限公司 | 工程化免疫效应细胞及其与CBL-b抑制剂联用的应用 |
| WO2023250097A1 (en) | 2022-06-22 | 2023-12-28 | Nurix Therapeutics, Inc. | Combination therapies with cbl-b inhibitor compounds and antiemetic agents |
| CN119998282A (zh) * | 2022-07-12 | 2025-05-13 | 热点治疗公司 | 固体形式和使用方法 |
| EP4554582A1 (en) * | 2022-07-12 | 2025-05-21 | Hotspot Therapeutics, Inc. | Cbl-b inhibitor, compositions comprising a cbl-b inhibitor in a method of treating a disease associated with cell proliferation |
| EP4554930A1 (en) * | 2022-07-12 | 2025-05-21 | Hotspot Therapeutics, Inc. | Methods of preparation of heterocyclic compounds |
| JP2025523057A (ja) * | 2022-07-12 | 2025-07-17 | ホットスポット セラピューティクス インコーポレイテッド | がん処置における使用のためのｃｂｌ－ｂ阻害剤及び抗ｐｄ１／抗ｐｄ－ｌ１ |
| AR129946A1 (es) * | 2022-07-18 | 2024-10-16 | Insilico Medicine Ip Ltd | Inhibidores de cbl-b y métodos de uso de los mismos |
| US20260028336A1 (en) | 2022-07-20 | 2026-01-29 | Arcus Biosciences, Inc. | Cbl-b inhibitors and methods of use thereof |
| JP2025525947A (ja) | 2022-08-16 | 2025-08-07 | グレンマーク ファーマシューティカルズ エルティーディー | Ｃｂｌ－ｂ阻害剤としての置換ピリジノン化合物 |
| WO2024062363A1 (en) * | 2022-09-21 | 2024-03-28 | Glenmark Pharmaceuticals Ltd | Bicyclic heterocyclic compounds as cbl-b inhibitors |
| WO2024074977A1 (en) * | 2022-10-04 | 2024-04-11 | Pfizer Inc. | Substituted 1 h-pyrazolo-pyridine and-pyrimidine compounds |
| WO2024081311A1 (en) * | 2022-10-11 | 2024-04-18 | Nimbus Clio, Inc. | Cbl-b modulators and uses thereof |
| WO2024086730A1 (en) * | 2022-10-19 | 2024-04-25 | Hotspot Therapeutics, Inc. | Heterocyclic cbl-b inhibitors for the treatment of cancer |
| WO2024105563A1 (en) * | 2022-11-16 | 2024-05-23 | Pfizer Inc. | Substituted bicyclic pyridone derivatives |
| WO2024131939A1 (en) * | 2022-12-23 | 2024-06-27 | Insilico Medicine Ip Limited | Cbl-b inhibitors and methods of uses thereof |
| WO2024155710A1 (en) | 2023-01-18 | 2024-07-25 | Biomea Fusion, Inc. | Crystalline forms of n-[4-[4-(4-morpholinyl)-7h-pyrrolo[2,3-d]pyrimidin-6- yl]phenyl]-4-[[3(r)-[(l-oxo-2-propen-l-yl)amino]-l-piperidinyl]methyl]-2-pyridinecarboxamide as a covalent inhibitor of menin-mll interaction |
| CN120584113A (zh) * | 2023-01-19 | 2025-09-02 | 广州宇繁南图生物科技有限公司 | 一种杂环化合物及其制备方法和应用 |
| WO2024153246A1 (zh) * | 2023-01-20 | 2024-07-25 | 海南先声再明医药股份有限公司 | 取代的三环化合物及其应用 |
| TW202435863A (zh) | 2023-01-28 | 2024-09-16 | 芬蘭商奧利安公司 | Cbl-b抑制劑 |
| EP4705292A1 (en) | 2023-05-05 | 2026-03-11 | Arcus Biosciences, Inc. | Cbl-b inhibitors and methods of use thereof |
| AR132644A1 (es) | 2023-05-09 | 2025-07-16 | Genentech Inc | 3-fenil-isoindolin-1-onas 6-sustituidas, como inhibidores selectivos de cbl-b sobre c-cbl |
| US20250011318A1 (en) | 2023-05-25 | 2025-01-09 | Arcus Biosciences, Inc. | Cbl-b inhibitors and methods of use thereof |
| WO2024255762A1 (zh) * | 2023-06-13 | 2024-12-19 | 上海齐鲁制药研究中心有限公司 | Cbl-b抑制剂 |
| CN121816192A (zh) | 2023-09-14 | 2026-04-07 | 因斯布鲁克医科大学 | 通过抑制NR2f6增强CAR-T细胞疗效 |
| WO2025223343A1 (zh) * | 2024-04-22 | 2025-10-30 | 杭州中美华东制药有限公司 | 作为Cbl-b抑制剂的化合物 |
| WO2025243317A1 (en) * | 2024-05-20 | 2025-11-27 | Jubilant Biosys Limited | Substituted bicyclic sulfonamide derivatives as modulators of cbl-b |
| WO2026022749A2 (en) | 2024-07-26 | 2026-01-29 | Aurigene Oncology Limited | Cbl-b inhibitors |
| WO2026040995A1 (zh) * | 2024-08-19 | 2026-02-26 | 北京望实智慧科技有限公司 | 用作Cbl-b抑制剂的化合物 |
| CN120000656B (zh) * | 2025-03-20 | 2025-11-07 | 北京大学 | 小分子化合物nx-1607在制备治疗肝纤维化的产品中的应用 |
Family Cites Families (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5192553A (en) | 1987-11-12 | 1993-03-09 | Biocyte Corporation | Isolation and preservation of fetal and neonatal hematopoietic stem and progenitor cells of the blood and methods of therapeutic use |
| US6352694B1 (en) | 1994-06-03 | 2002-03-05 | Genetics Institute, Inc. | Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells |
| US5273986A (en) | 1992-07-02 | 1993-12-28 | Hoffmann-La Roche Inc. | Cycloalkylthiazoles |
| US5827642A (en) | 1994-08-31 | 1998-10-27 | Fred Hutchinson Cancer Research Center | Rapid expansion method ("REM") for in vitro propagation of T lymphocytes |
| EP1227321A1 (en) | 2000-12-28 | 2002-07-31 | Institut für Bioanalytik GmbH | Reversible MHC multimer staining for functional purification of antigen-specific T cells |
| CA2437248A1 (en) | 2001-02-02 | 2002-08-15 | Takeda Chemical Industries, Ltd. | Jnk inhibitor |
| WO2004099388A2 (en) | 2003-03-05 | 2004-11-18 | Proteologics, Inc. | Cbl-b polypeptides, complexes and related methods |
| US7320992B2 (en) | 2003-08-25 | 2008-01-22 | Amgen Inc. | Substituted 2,3-dihydro-1h-isoindol-1-one derivatives and methods of use |
| CN101365806B (zh) | 2005-12-01 | 2016-11-16 | 医学预后研究所 | 用于鉴定治疗反应的生物标记的方法和装置及其预测疗效的用途 |
| ES2566502T3 (es) | 2006-09-13 | 2016-04-13 | The Trustees Of Columbia University In The City Of New York | Agentes y métodos para provocar una respuesta inmune antitumoral |
| AT506041A1 (de) | 2007-12-10 | 2009-05-15 | Univ Innsbruck | Verfahren zur erhöhung der immunreaktivität |
| CA2710462C (en) | 2008-02-05 | 2015-11-24 | F. Hoffmann-La Roche Ag | Pyridinones and pyridazinones |
| AR079545A1 (es) | 2009-12-21 | 2012-02-01 | Bayer Cropscience Ag | Tienilpiri(mi)dinilazol |
| KR101862327B1 (ko) | 2010-05-07 | 2018-05-29 | 질레드 코네티컷 인코포레이티드 | 피리돈 및 아자-피리돈 화합물 및 사용 방법 |
| MX342995B (es) | 2010-07-13 | 2016-10-21 | Anthrogenesis Corp | Métodos de generar células asesinas naturales. |
| AR082590A1 (es) | 2010-08-12 | 2012-12-19 | Hoffmann La Roche | Inhibidores de la tirosina-quinasa de bruton |
| EP2471548A1 (de) | 2010-12-28 | 2012-07-04 | Apeiron Biologics AG | siRNA gegen Cbl-b und optional IL2 und IL12 zur Verwendung in der Behandlung von Krebs |
| WO2012175513A1 (en) | 2011-06-20 | 2012-12-27 | Bayer Intellectual Property Gmbh | Thienylpyri(mi)dinylpyrazole |
| US20130110678A1 (en) | 2011-11-02 | 2013-05-02 | Apple Inc. | Purchasing a product in a store using a mobile device |
| WO2013067264A1 (en) | 2011-11-03 | 2013-05-10 | Genentech, Inc. | 8-fluorophthalazin-1 (2h) - one compounds as inhibitors of btk activity |
| UA111756C2 (uk) | 2011-11-03 | 2016-06-10 | Ф. Хоффманн-Ля Рош Аг | Сполуки гетероарилпіридону та азапіридону як інгібітори тирозинкінази брутона |
| CA2861066C (en) | 2012-01-12 | 2024-01-02 | Yale University | Compounds and methods for the enhanced degradation of targeted proteins and other polypeptides by an e3 ubiquitin ligase |
| KR20150054994A (ko) | 2012-09-13 | 2015-05-20 | 에프. 호프만-라 로슈 아게 | 브루톤 티로신 키나아제의 억제제 |
| US10308707B2 (en) | 2013-12-02 | 2019-06-04 | Aaron Diamond Aids Research Center | Bispecific HIV-1-neutralizing antibodies |
| AU2014360446A1 (en) | 2013-12-05 | 2016-06-09 | Pharmacyclics, Llc | Inhibitors of Bruton's tyrosine kinase |
| RU2763795C2 (ru) | 2014-04-23 | 2022-01-11 | Джуно Терапьютикс, Инк. | Способы выделения, культивирования и генетической инженерии популяций клеток иммунной системы для адоптивной терапии |
| AU2015289644A1 (en) | 2014-07-15 | 2017-02-02 | Juno Therapeutics, Inc. | Engineered cells for adoptive cell therapy |
| JP6507234B2 (ja) * | 2014-10-02 | 2019-04-24 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | ブルトンチロシンキナーゼ（ｂｔｋ）によって介入される障害の処置における使用のためのピラゾールカルボキサミド化合物 |
| BR112017025986A2 (pt) | 2015-06-02 | 2018-08-14 | Pharmacyclics Llc | inibidores de tirosina quinase de bruton. |
| EP3325475B1 (en) | 2015-07-17 | 2020-03-18 | Takeda Pharmaceutical Company Limited | Oxadiazole derivatives useful as hdac inhibitors |
| EP3138905A1 (en) | 2015-09-04 | 2017-03-08 | Miltenyi Biotec GmbH | Method for natural killer cell expansion |
| CN108884140B (zh) | 2015-12-03 | 2022-10-25 | 朱诺治疗学股份有限公司 | 修饰的嵌合受体及相关组合物和方法 |
| EP3254701A1 (en) | 2016-06-09 | 2017-12-13 | IMBA-Institut für Molekulare Biotechnologie GmbH | Cbl-b inhibitor comprising a cbl-b binding peptide for the prevention or treatment of fungal infections |
| US10842878B2 (en) | 2016-11-22 | 2020-11-24 | Dana-Farber Cancer Institute, Inc. | Degradation of Bruton's tyrosine kinase (BTK) by conjugation of BTK inhibitors with E3 ligase ligand and methods of use |
| WO2019148005A1 (en) * | 2018-01-26 | 2019-08-01 | Nurix Therapeutics, Inc. | Inhibitors of cbl-b and methods of use thereof |
| JP7600123B2 (ja) | 2018-10-15 | 2024-12-16 | ニューリックス セラピューティクス，インコーポレイテッド | ユビキチンプロテオソーム経路を介してｂｔｋを分解するための二官能性化合物 |
| WO2020167518A1 (en) | 2019-02-13 | 2020-08-20 | Nurix Therapeutics, Inc. | Bifunctional compounds for degrading btk via ubiquitin proteosome pathway |
| EP3953346A1 (en) | 2019-04-09 | 2022-02-16 | Nurix Therapeutics, Inc. | 3-substituted piperidine compounds for cbl-b inhibition, and use of a cbl-b inhibitor in combination with a cancer vaccine and/or oncolytic virus |
| EP3969447A1 (en) | 2019-05-17 | 2022-03-23 | Nurix Therapeutics, Inc. | Cyano cyclobutyl compounds for cbl-b inhibition and uses thereof |
| MX2021015675A (es) | 2019-06-26 | 2022-02-03 | Nurix Therapeutics Inc | Compuestos de bencil-triazol sustituidos para la inhibicion de cbl-b y otros usos de los mismos. |
| WO2021021761A1 (en) | 2019-07-30 | 2021-02-04 | Nurix Therapeutics, Inc. | Urea, amide, and substituted heteroaryl compounds for cbl-b inhibition |
| EP4034141A1 (en) | 2019-09-24 | 2022-08-03 | Nurix Therapeutics, Inc. | Cbl inhibitors and compositions for expansion of immune cells |
| US20230024442A1 (en) | 2019-11-08 | 2023-01-26 | Nurix Therapeutics, Inc. | Bifunctional compounds for grading btk via ubiquitin proteosome pathway |
| US11820781B2 (en) | 2019-12-04 | 2023-11-21 | Nurix Therapeutics, Inc. | Bifunctional compounds for degrading BTK via ubiquitin proteosome pathway |
| US12016860B2 (en) | 2021-04-08 | 2024-06-25 | Nurix Therapeutics, Inc. | Combination therapies with Cbl-b inhibitor compounds |
-
2020
- 2020-06-26 MX MX2021015675A patent/MX2021015675A/es unknown
- 2020-06-26 CA CA3294689A patent/CA3294689A1/en active Pending
- 2020-06-26 WO PCT/US2020/039957 patent/WO2020264398A1/en not_active Ceased
- 2020-06-26 AU AU2020303696A patent/AU2020303696B2/en active Active
- 2020-06-26 BR BR112021026241A patent/BR112021026241A2/pt unknown
- 2020-06-26 EP EP20742593.5A patent/EP3990117A1/en active Pending
- 2020-06-26 IL IL289290A patent/IL289290B1/en unknown
- 2020-06-26 US US16/913,949 patent/US11401267B2/en active Active
- 2020-06-26 CN CN202080060696.0A patent/CN114364670B/zh active Active
- 2020-06-26 KR KR1020227001977A patent/KR20220026581A/ko active Pending
- 2020-06-26 CA CA3144450A patent/CA3144450A1/en active Pending
- 2020-06-26 JP JP2021577171A patent/JP7831995B2/ja active Active
-
2021
- 2021-12-15 MX MX2025000627A patent/MX2025000627A/es unknown
-
2022
- 2022-06-29 US US17/853,904 patent/US12234230B2/en active Active
-
2024
- 2024-10-25 US US18/927,712 patent/US20250136590A1/en active Pending
-
2026
- 2026-03-17 AU AU2026202030A patent/AU2026202030A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| MX2025000627A (es) | 2025-03-07 |
| JP2022538174A (ja) | 2022-08-31 |
| US12234230B2 (en) | 2025-02-25 |
| KR20220026581A (ko) | 2022-03-04 |
| US20250136590A1 (en) | 2025-05-01 |
| JP7831995B2 (ja) | 2026-03-17 |
| US20210053961A1 (en) | 2021-02-25 |
| AU2020303696A1 (en) | 2022-01-06 |
| IL289290A (en) | 2022-02-01 |
| CA3144450A1 (en) | 2020-12-30 |
| IL289290B1 (en) | 2026-04-01 |
| US11401267B2 (en) | 2022-08-02 |
| CA3294689A1 (en) | 2026-03-02 |
| AU2020303696B2 (en) | 2026-04-09 |
| EP3990117A1 (en) | 2022-05-04 |
| BR112021026241A2 (pt) | 2022-06-07 |
| US20230150991A1 (en) | 2023-05-18 |
| AU2026202030A1 (en) | 2026-04-02 |
| CN114364670B (zh) | 2025-06-13 |
| WO2020264398A1 (en) | 2020-12-30 |
| CN114364670A (zh) | 2022-04-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2021015675A (es) | Compuestos de bencil-triazol sustituidos para la inhibicion de cbl-b y otros usos de los mismos. | |
| MX2021013751A (es) | Compuestos de ciano ciclobutilo para la inhibicion del protooncogen b de linfoma de linaje b de casitas (cbl-b) y usos de los mismos. | |
| BR112021019722A2 (pt) | Compostos de piperidina 3-substituídos para inibição de cbl-b, e uso de inibidor de cbl-b em combinação com vacina contra câncer e/ou vírus oncolítico | |
| MX2022001199A (es) | Compuestos de urea, amida y heteroarilo sustituido para la inhibicion de cbl-b. | |
| ECSP22023220A (es) | Derivados de indol mono o disustituidos como inhibidores de la replicación viral del dengue | |
| ECSP20020410A (es) | Inhibidores de la ectonucleótido pirofosfatasa-fosfodiesterasa 1 (enpp-1) y usos de los mismos | |
| MX2023009011A (es) | Inhibidor de cdk. | |
| NI201100056A (es) | Compuestos de multiheteroarilo como inhibidores de prostaglandina d sintasa hematopoyética y su uso para tratar enfermedades mediadas por prostaglandina d2. | |
| MX2019002750A (es) | Derivados de pirazolopiridina como moduladores de cinasa 1 progenitora hematopoyetica (hpk1) y usos de los mismos para tratamiento de cancer. | |
| CL2020002698A1 (es) | Moduladores de enzimas modificadoras de metilo, composiciones y usos de estos | |
| UY36903A (es) | Derivados de indol mono- o disustituidos como inhibidores de la replicación viral del dengue | |
| AU2012242871A8 (en) | Fused imidazole derivatives useful as IDO inhibitors | |
| GT201400009A (es) | 4-imidazopiridazin-1-il-benzamidas y 4-imidazotriazin-1-il-benzamidas como inhibidores de btk | |
| GT201500020A (es) | Sulfamoilarilamidas y su uso como medicamentos para el tratamiento de la hepatitis b | |
| UY36904A (es) | Derivados de indol mono- o disustituidos como inhibidores de la replicación viral del dengue | |
| UY33440A (es) | ?compuestos pirimidinílicos para uso como inhibidores de atr?. | |
| NI201000003A (es) | Derivados de pirimidina trisustituida para el tratamiento de enfermedades proliferativas. | |
| CR11200A (es) | Derivados de morfolino pirimidina utilizados en enfermedades relacionadas con mtor quinasa y/o p13k | |
| BR112017006299A2 (pt) | derivados indol mono- ou dissubstituídos como inibidores da replicação viral da dengue | |
| UY35088A (es) | Inhibidores de glutamina sintetasa de planta y métodos para su identificación | |
| CL2015000608A1 (es) | Formulaciones de daptomicina y usos de la misma | |
| MX2023007265A (es) | Inhibidores de cdk y su uso como productos farmacéuticos. | |
| CL2020001358A1 (es) | Cepa vacunal de brucella modificada para el tratamiento de brucelosis | |
| MX2019013862A (es) | Terapia de combinacion. | |
| MX2017011018A (es) | Inhibicion de la actividad de olig2. |